secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001140361-26-007249
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 5.03, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre acquires Cullgen for ~$300M in stock; gains TPD/DAC platform, new CEO appointed
--------------------------------------------------------------------------------

- All-stock acquisition values Cullgen at ~$300M; expected close early Q2 2026; Cullgen becomes wholly owned subsidiary.
- Ying Luo (Cullgen CEO) appointed CEO/President and director of Gyre; Ping Zhang remains Executive Chairman; Thomas Eastling and Songjiang Ma resign from board.
- Combined entity has commercial ETUARY® (lung fibrosis, China) and Hydronidone (F351) nearing NDA, plus Cullgen's preclinical/clinical TPD/DAC pipeline.
- Issuance of Series B Convertible Preferred Stock; conversion requires stockholder approval; insiders subject to 180-day to 18-month lock-up agreements.
- Support agreements from key Gyre and Cullgen stockholders to vote in favor of conversion proposal and merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036126007249/0001140361-26-007249-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036126007249/ef20066398_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-007249

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer